Literature DB >> 25857295

Interfering parameters in the determination of urinary globotriaosylceramide (Gb3) in patients with chronic kidney disease.

Martina Gaggl1, Marlene Hofer2, Stefanie Weidner2, Julia Kleinert2, Günter Fauler3, Manfred Wallner4, Peter Kotanko5, Eduard Paschke6, Gere Sunder-Plassmann2.   

Abstract

INTRODUCTION: Globotriaosylceramide (Gb3, CD77) represents a pivotal part of the cell membrane. Measuring the urinary Gb3 content can be used to screen patients with chronic kidney disease (CKD) for Fabry disease, a disorder caused by hampered Gb3 degradation. However, little is known about factors influencing urinary Gb3 excretion other than Fabry disease. The aim of the present study was to identify routine diagnostic parameters as predictors of urinary Gb3 excretion in patients with CKD.
METHODS: Our study included 609 subjects with CKD stage I-V. We analyzed the influence of age, gender, renal function, urinary cell content and chemical characteristics on urinary Gb3 concentrations (total Gb3, Gb3-24 isoform, and Gb3-24:18 isoform ratio), determined by direct electrospray ionization mass spectrometry.
RESULTS: In 609 subjects the median total urinary Gb3 was 233 ng/mg and the Gb3-24:18 isoform ratio was 1.2. Twenty-one patients, none of whom had Fabry disease, had a Gb3-24:18 isoform ratio ≥2.3. Females excreted a higher total amount of Gb3, but the Gb3-24:18 isoform ratio was comparable to males. Renal function and age had no influence on total Gb3, Gb3 isoforms or the ratio. Only a distinct load of bacteria and leukocytes was associated with an increased Gb3 excretion. Urinary leukocytes, erythrocytes, bacteria, or protein content did not affect the Gb3-24:18 isoform ratio.
CONCLUSION: The Gb3-24:18 isoform ratio is unaffected by several potential influencing variables and may thus be applied for screening for Fabry disease in unselected cohorts of patients presenting with CKD.

Entities:  

Keywords:  Chronic kidney disease; Fabry disease; Globotriaosylceramide; Lysosomal storage disorder

Mesh:

Substances:

Year:  2015        PMID: 25857295     DOI: 10.1007/s40620-015-0193-1

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  29 in total

1.  Urinary total globotriaosylceramide and isoforms to identify women with Fabry disease: a diagnostic test study.

Authors:  Eduard Paschke; Guenter Fauler; Heimo Winkler; Axel Schlagenhauf; Barbara Plecko; Wolfgang Erwa; Frank Breunig; Wolfgang Urban; Bojan Vujkovac; Gere Sunder-Plassmann; Peter Kotanko
Journal:  Am J Kidney Dis       Date:  2010-12-24       Impact factor: 8.860

2.  Is globotriaosylceramide a useful biomarker in Fabry disease?

Authors:  E Young; K Mills; P Morris; A Vellodi; P Lee; S Waldek; B Winchester
Journal:  Acta Paediatr Suppl       Date:  2005-03

3.  Direct tandem mass spectrometric profiling of sulfatides in dry urinary samples for screening of metachromatic leukodystrophy.

Authors:  Ladislav Kuchař; Befekadu Asfaw; Helena Poupětová; Jitka Honzíková; František Tureček; Jana Ledvinová
Journal:  Clin Chim Acta       Date:  2013-07-06       Impact factor: 3.786

4.  Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in Fabry mice.

Authors:  Brandon Durant; Sabrina Forni; Lawrence Sweetman; Nastry Brignol; Xing-Li Meng; Elfrida R Benjamin; Raphael Schiffmann; Jin-Song Shen
Journal:  J Lipid Res       Date:  2011-07-11       Impact factor: 5.922

5.  Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry.

Authors:  Kevin Mills; Andrew Johnson; Bryan Winchester
Journal:  FEBS Lett       Date:  2002-03-27       Impact factor: 4.124

6.  Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease.

Authors:  K Mills; P Morris; P Lee; A Vellodi; S Waldek; E Young; B Winchester
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

7.  Fabry disease: detection of heterozygotes by examination of glycolipids in urinary sediment.

Authors:  W J Cable; R H McCluer; E H Kolodny; M D Ullman
Journal:  Neurology       Date:  1982-10       Impact factor: 9.910

8.  Lisinopril decreases plasma free testosterone in male hypertensive patients and increases sex hormone binding globulin in female hypertensive patients.

Authors:  H Koshida; R Takeda; I Miyamori
Journal:  Hypertens Res       Date:  1998-12       Impact factor: 3.872

9.  Quantitative determination of the neutral glycosyl ceramides in human blood.

Authors:  D E Vance; C C Sweeley
Journal:  J Lipid Res       Date:  1967-11       Impact factor: 5.922

10.  Risk of death in heart disease is associated with elevated urinary globotriaosylceramide.

Authors:  Raphael Schiffmann; Sabrina Forni; Caren Swift; Nastry Brignol; Xiaoyang Wu; David J Lockhart; Derek Blankenship; Xuan Wang; Paul A Grayburn; Matthew R G Taylor; Brian D Lowes; Maria Fuller; Elfrida R Benjamin; Lawrence Sweetman
Journal:  J Am Heart Assoc       Date:  2014-02-04       Impact factor: 5.501

View more
  2 in total

1.  Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.

Authors:  Hernán Trimarchi; Romina Canzonieri; Amalia Schiel; Juan Politei; Aníbal Stern; José Andrews; Matías Paulero; Tatiana Rengel; Alicia Aráoz; Mariano Forrester; Fernando Lombi; Vanesa Pomeranz; Romina Iriarte; Pablo Young; Alexis Muryan; Elsa Zotta
Journal:  J Nephrol       Date:  2016-02-03       Impact factor: 3.902

2.  Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy.

Authors:  Martina Gaggl; Natalija Lajic; Georg Heinze; Till Voigtländer; Raute Sunder-Plassmann; Eduard Paschke; Günter Fauler; Gere Sunder-Plassmann; Gerald Mundigler
Journal:  Int J Med Sci       Date:  2016-04-26       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.